WALTHAM, Mass. – Glytec’s eGlycemic Management System helps reduce hospital readmissions, two new studies have found.
“The data indicates a direct correlation between risk-adjusted readmission rates and tight glycemic control for our cardiovascular patients,” said April Mumpower, BSH of Mountain States Health Alliance, one of the study’s leads, in a press release.
The two studies achieved reduced readmissions for patient populations at the center of new at-risk and value based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).
The studies compared outcomes of cardiovascular patients receiving care with eGMS to outcomes of cardiovascular patients receiving standard care. Those receiving care with eGMS returned to the hospital far less frequently, with reductions in risk-adjusted 30-day readmissions as high as 68%.
One of the key benefits of Glytec’s eGMS is the GlucoSurveillance module that alerts care teams to patients with blood glucose outside a designated range. The module interfaces directly with laboratory information systems to perform continuous enterprise-wide surveillance.
The basis for the two studies was formed in response to a system-wide glycemic initiative launched by Mountain States Health Alliance. The researchers recognized that patients admitted and discharged with elevated blood glucose have higher incidence of complications, longer lengths of stays and increased rates of readmission.
“These studies validate our hypothesis that using Glytec’s automated surveillance, insulin dosing and analytics to achieve these goals has a sizable impact on the outcomes we’re able to achieve,” said Tamera Parsons, CPHQ of Blue Mountain States Health Alliance, and the co-lead of the studies.